Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
American Journal of Respiratory and Critical Care Medicine
|
September 13, 2003
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis
Claudia L Ordoñez, Noreen R Henig, Nicole Mayer-Hamblett, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
May 3, 2017
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations
Don B Sanders, George M Solomon, Valeria V Beckett, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 20, 2021
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis
J Stuart Elborn, Michael W Konstan, Jennifer L Taylor-Cousar, et al.
Plos One
|
December 28, 2020
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial
Graham Devereux, Danielle Wrolstad, Stephen J Bourke, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 25, 2018
Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial
Scott D Sagel, Umer Khan, Raksha Jain, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension Study
Cori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
The European Respiratory Journal
|
November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension study
Cori L Daines, Elizabeth Tullis, Stefano Costa, et al.
JAMA Pediatrics
|
May 5, 2015
Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trial
Scott W Powers, Lori J Stark, Leigh A Chamberlin, et al.
BMC Medical Research Methodology
|
April 28, 2019
Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis
Theodore G Liou, Frederick R Adler, Natalia Argel, et al.
Pediatrics
|
February 14, 2018
Structure and Functions of Pediatric Aerodigestive Programs: A Consensus Statement
R Paul Boesch, Karthik Balakrishnan, Sari Acra, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
American Journal of Respiratory and Critical Care Medicine
|
September 13, 2003
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis
Claudia L Ordoñez, Noreen R Henig, Nicole Mayer-Hamblett, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
May 3, 2017
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations
Don B Sanders, George M Solomon, Valeria V Beckett, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 20, 2021
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis
J Stuart Elborn, Michael W Konstan, Jennifer L Taylor-Cousar, et al.
Plos One
|
December 28, 2020
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial
Graham Devereux, Danielle Wrolstad, Stephen J Bourke, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 25, 2018
Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial
Scott D Sagel, Umer Khan, Raksha Jain, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension Study
Cori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
The European Respiratory Journal
|
November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension study
Cori L Daines, Elizabeth Tullis, Stefano Costa, et al.
JAMA Pediatrics
|
May 5, 2015
Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trial
Scott W Powers, Lori J Stark, Leigh A Chamberlin, et al.
BMC Medical Research Methodology
|
April 28, 2019
Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis
Theodore G Liou, Frederick R Adler, Natalia Argel, et al.
Pediatrics
|
February 14, 2018
Structure and Functions of Pediatric Aerodigestive Programs: A Consensus Statement
R Paul Boesch, Karthik Balakrishnan, Sari Acra, et al.
Page
of 5